ClinicalTrials.gg
CompletedNCT06342947HERALDUpdated Feb 17, 2025

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)

A Phase 2 interventional study of ALG-055009 and Placebo in NASH, MASH and Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Aligos Therapeutics. Completed at 40 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Aligos Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
161st of 460
102 · median 56
Started
2024
with 28 others
Phase 2
192 of 547
15 open now
Registered
511th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 161st largest by enrollment of the 460 interventional ones that give a count, is one of 29 that started in 2024, is one of 192 in phase 2, and was the 511th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.

Read the detailed description

This is a double-blind, randomized, placebo-controlled Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks. The study will be conducted in approximately 100 adult non-cirrhotic subjects with presumed MASH and liver fibrosis (F1-F3). The study will be conducted at up to approximately 45 sites throughout the United States of America.

03

Conditions studied

  • NASH
  • MASH
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Nonalcoholic Steatohepatitis

Keywords

  • NASH
  • MASH
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Liver
  • Fatty Liver Disease
  • Liver Disease
  • THR-B
  • THR B
  • THR-β
  • THR β
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female, 18 to 75 years of age
  • (BMI) ≥ 25 kg/m2
  • Diagnosis of presumed NASH/MASH with F1-F3 liver fibrosis based on one of the following:

    • Liver within 6 months prior to screening showing a NAFLD activity score (NAS) of ≥4 with at least a score of 1 in each of the NAS components; OR
    • Having ≥2 metabolic syndrome criteria and a screening FibroScan liver stiffness measurement between 7 - 20 kPa
  • Screening FibroScan with CAP score of >300 dB/m
  • Screening MRI-PDFF with ≥10% liver fat content

Key Exclusion Criteria:

  • History or clinical evidence of chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD)
  • History or current evidence of cirrhosis
  • History of liver transplantation or known planned liver transplantation
  • History or current evidence of a pituitary disorder or hyperthyroidism
  • Untreated clinical or subclinical hypothyroidism; or on thyroid replacement therapy at screening or within the last 6 months prior to screening.
  • TSH, free T4, or Total T3 >1.1 x or \<0.9 x LLN
  • Clinically concerning abnormal or cardiac history
  • ≥9.5%
  • count ≤135,000/mm3
  • or AST >5 x ULN
  • >1.3
  • Albumin \<3.5 g/dL
  • \<45 mL/min/1.73 m2
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    ALG-055009 softgel capsule 0.3mg

    ALG-055009 softgel capsule 0.3mg Daily for 12 weeks

    Drug: ALG-055009

  • Experimental
    ALG-055009 softgel capsule 0.5mg

    ALG-055009 softgel capsule 0.5mg Daily for 12 weeks

    Drug: ALG-055009

  • Experimental
    ALG-055009 softgel capsule 0.7mg

    ALG-055009 softgel capsule 0.7mg Daily for 12 weeks

    Drug: ALG-055009

  • Experimental
    ALG-055009 softgel capsule 0.9mg

    ALG-055009 softgel capsule 0.9mg Daily for 12 weeks

    Drug: ALG-055009

  • Placebo comparator
    Placebo

    Placebo softgel capsule Daily for 12 weeks

    Drug: Placebo

Interventions

  • Softgel Capsule

  • DrugPlacebo

    Softgel Capsule

06

What researchers measure

Primary outcomes

  1. Percent relative change from baseline in liver fat content

    Percent relative change from baseline in liver fat content by MRI-PDFF at Week 12

    Time frame: 12 weeks

Secondary outcomes

  1. Absolute change from baseline in liver fat content

    Absolute change from baseline in liver fat content by MRI-PDFF at Week 12

    Time frame: 12 weeks

  2. Proportion of subjects with ≥30% relative reduction in liver fat content

    Proportion of subjects with ≥30% relative reduction in liver fat content by MRI-PDFF at Week 12

    Time frame: 12 weeks

  3. Proportion of subjects with ≥50% relative reduction in liver fat content

    Proportion of subjects with ≥50% relative reduction in liver fat content by MRI-PDFF at Week 12

    Time frame: 12 weeks

  4. Proportion of subjects with ≥70% relative reduction in liver fat content

    Proportion of subjects with ≥70% relative reduction in liver fat content by MRI-PDFF at Week 12

    Time frame: 12 weeks

  5. Proportion of subjects with normalization (<5%) in liver fat content

    Proportion of subjects with normalization (\<5%) in liver fat content by MRI-PDFF at Week 12

    Time frame: 12 weeks

Other outcomes

  1. Change from baseline (absolute/percent) in lipid/lipoprotein levels

    Change from baseline (absolute/percent) in lipid/lipoprotein levels at Week 12

    Time frame: 12 weeks

  2. Change from baseline (absolute/percent) in SHBG

    Change from baseline (absolute/percent) in SHBG

    Time frame: up to 16 weeks

  3. Change from baseline (absolute/percent) alanine aminotransferase (ALT)

    Change from baseline (absolute/percent) in alanine aminotransferase (ALT) at Week 12

    Time frame: 12 weeks

  4. Change from baseline (absolute/percent) aspartate aminotransferase (AST)

    Change from baseline (absolute/percent) in aspartate aminotransferase (AST) at Week 12

    Time frame: 12 weeks

  5. Safety and tolerability will be assessed by monitoring TEAEs

    Safety and tolerability will be assessed by monitoring TEAEs

    Time frame: 16 weeks

  6. Safety and tolerability will be assessed by monitoring 12-lead electrocardiograms (ECGs)

    Safety and tolerability will be assessed by monitoring 12-lead electrocardiograms (ECGs)

    Time frame: 16 weeks

  7. PK parameters of ALG-055009 in plasma, AUCs

    PK parameters of ALG-055009 in plasma, AUCs

    Time frame: 12 weeks

  8. PK parameters of ALG-055009 in plasma, Tmax

    PK parameters of ALG-055009 in plasma, Tmax

    Time frame: 12 weeks

  9. PK parameters of ALG-055009 in plasma, Cmax

    PK parameters of ALG-055009 in plasma, Cmax

    Time frame: 12 weeks

  10. PK parameters of ALG-055009 in plasma, Cmin

    PK parameters of ALG-055009 in plasma, Cmin

    Time frame: 12 weeks

07

Study locations

40 sites
  • Aligos Clinical Study Site 18
    Chandler, Arizona 85224, United States
  • Aligos Clinical Study Site 15
    Peoria, Arizona 85301, United States
  • Aligos Clinical Study Site 17
    Tucson, Arizona 85641, United States
  • Aligos Clinical Study Site 35
    Chula Vista, California 91902, United States
  • Aligos Clinical Study Site 1
    Lincoln, California 95648, United States
  • Aligos Clinical Study Site 37
    Poway, California 92025, United States
  • Aligos Clinical Study Site 10
    Rialto, California 92316, United States
  • Aligos Clinical Study Site 26
    Bradenton, Florida 34205, United States
  • Aligos Clinical Study Site 25
    Clearwater, Florida 33755, United States
  • Aligos Clinical Study Site 39
    Fort Myers, Florida 33901, United States
  • Aligos Clinical Study Site 2
    Maitland, Florida 32751, 32794, United States
  • Aligos Clinical Study Site 22
    Ocoee, Florida 32703, United States
  • Aligos Clinical Study Site 32
    Port Orange, Florida 32119, United States
  • Aligos Clinical Study Site 38
    Sarasota, Florida 34230, United States
  • Aligos Clinical Study Site 31
    The Villages, Florida 32159, United States
  • Aligos Clinical Study Site 3
    Viera, Florida 32924, United States
  • Aligos Clinical Study Site 30
    Winter Park, Florida 32789, United States
  • Aligos Clinical Study Site 23
    Athens, Georgia 30601, United States
  • Aligos Clinical Study Site 12
    Topeka, Kansas 66546, United States
  • Aligos Clinical Study Site 29
    Louisville, Kentucky 40018, United States
  • Aligos Clinical Study Site 24
    Bastrop, Louisiana 71220, United States
  • Aligos Clinical Study Site 5
    Houma, Louisiana 70360, United States
  • Aligos Clinical Study Site 4
    Marrero, Louisiana 70072, United States
  • Aligos Clinical Study Site 6
    Metairie, Louisiana 70001, United States
  • Aligos Clinical Study Site 14
    Chesterfield, Michigan 48047, United States
  • Aligos Clinical Study Site 7
    New York, New York 10001, United States
  • Aligos Clinical Study Site 8
    Morehead City, North Carolina 28557, United States
  • Aligos Clinical Study Site 21
    Columbus, Ohio 43004, United States
  • Aligos Clinical Study Site 16
    Westlake, Ohio 44145, United States
  • Aligos Clinical Study Site 36
    East Greenwich, Rhode Island 02818, United States
  • Aligos Clinical Study Site 9
    Nashville, Tennessee 37011, United States
  • Aligos Clinical Study Site 19
    Austin, Texas 73301, United States
  • Aligos Clinical Study Site 33
    Bellaire, Texas 77401, United States
  • Aligos Clinical Study Site 27
    Brownsville, Texas 78520, United States
  • Aligos Clinical Study Site 28
    Edinburg, Texas 78504, United States
  • Aligos Clinical Study Site 40
    Farmers Branch, Texas 75006, United States
  • Aligos Clinical Study Site 20
    San Antonio, Texas 78015, United States
  • Aligos Clinical Study Site 11
    Waco, Texas 76633, United States
  • Aligos Clinical Study Site 13
    Manassas, Virginia 20108, United States
  • Aligos Clinical Study Site 34
    Seattle, Washington 98039, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Aug 2024, 4 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 4 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Apr 2, 2024
StartActual
Apr 1, 2024
Primary completionActual
Aug 19, 2024
CompletionActual
Sep 9, 2024
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06342947
Lead sponsor
Aligos Therapeutics
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Apr 1, 2024
Primary completion
Aug 19, 2024
Completion
Sep 9, 2024
Last update
Feb 17, 2025

Study contacts

Stephen Harrison, MD
principal investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ALG-055009

Start the discussion